PlasmaSEQ
PlasmaSEQ Overview
Multiple myeloma continues to be one of the most challenging and resistant hematological malignancies inspite of the advent of so many newer therapies in the last decade. This has called into question our basis of classification of myeloma.
PlasmaSEQ lays the foundation for a revolution in myeloma diagnostics with an assay that looks at myeloma more closely that any assay before it.
Comparison with Conventional Diagnostics
While FISH tests have been the standard in myeloma for almost 2 decades now, it is extremely limiting in terms of resolution. FISH can in general only identify abnormalities that involve atleast 100k to 200k abnormal DNA molecules. PlasmaSEQ however can do this as a resolution of 1 abnormal DNA molecular thus bringing a new paradigm to myeloma care.
PlasmaSEQ
*To be released in upcoming Plasmaseq 2.0